^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CB CAR-NK019

    i
    Other names: CB CAR-NK019, anti-CD19 CAR-NK
    Associations

    News

    Trials
    Company:
    Zhejiang University
    Drug class:
    CD19 inhibitor, NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    Anti-CD19 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases (clinicaltrials.gov)
    P=N/A, N=15, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial
    |
    cyclophosphamide • CB CAR-NK019
    4ms
    Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=10, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • CB CAR-NK019
    6ms
    Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial
    |
    cyclophosphamide • CB CAR-NK019
    2years
    Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)
    P1, N=48, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression • CD20 negative
    |
    CB CAR-NK019
    over2years
    Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression • CD20 negative
    |
    CB CAR-NK019